Previous studies have established that the AKT and ERK signaling pathways contribute to the upregulation of PD-L1 expression in non-small cell lung cancer, multiple myeloma, and triple-negative breast cancer [27,49,50,51]. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.